Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Carmel, Indiana
- Most recent report
- 10-Q, filed Nov 9, 2026
- Incorporated
- Delaware
- Filings on record
- 234 filings
- On EDGAR
- CIK 1776111
- Fiscal year ends
- December
- Filer status
- Emerging growth company
Financials 8 of 9
News 8 of 29
Prospectuses and Registrations 8 of 11
- S-3ASR Automatic shelf registration Mar 12, 2026
- S-8 Registration statement for an employee plan Mar 12, 2026
- S-3 Shelf registration statement Nov 6, 2025
- 424B4 Final prospectus for an offering Sep 25, 2025
- S-1 Registration statement for an offering Sep 22, 2025
- S-8 Registration statement for an employee plan Mar 17, 2025
- S-8 Registration statement for an employee plan Sep 13, 2024
- 424B5 Prospectus supplement for an offering Sep 13, 2024
Proxies 5
Ownership 8 of 148
- 4 Insider reported a trade Nov 5, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Nov 5, 2026
- 144 Notice of a proposed sale of restricted stock Nov 4, 2026
- 4 Insider reported a trade Oct 22, 2026
- 3 Insider reported their initial holding Oct 22, 2026
- 144 Notice of a proposed sale of restricted stock Aug 17, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- SCHEDULE 13D/A Large holder reported an active stake, amended Aug 10, 2026
Other 8 of 32
- ARS Annual report sent to shareholders Apr 22, 2026
- EFFECT Notice that a registration became effective Dec 8, 2025
- CORRESP Reply to SEC staff Dec 4, 2025
- EFFECT Notice that a registration became effective Sep 24, 2025
- S-1MEF Sep 24, 2025
- CORRESP Reply to SEC staff Sep 22, 2025
- CORRESP Reply to SEC staff Sep 22, 2025
- UPLOAD Comment letter from SEC staff Aug 13, 2025
Everything here comes from MBX Biosciences, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.